Literature DB >> 24021800

Dyrk1A-mediated phosphorylation of RCAN1 promotes the formation of insoluble RCAN1 aggregates.

Woo-Joo Song1, Eun-Ah Christine Song, Sun-Hee Choi, Hyung-Hwan Baik, Byung Kwan Jin, Jeong Hee Kim, Sul-Hee Chung.   

Abstract

The mechanisms underlying aggregate formation in age-related neurodegenerative diseases remain not well understood. Here we investigated whether dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A (Dyrk1A) is involved in the formation of regulator of calcineurin 1 (RCAN1) aggregates. We show that RCAN1 self-associates and forms multimers, and that this process is promoted by the Dyrk1A-mediated phosphorylation of RCAN1 at the Thr(192) residue. Transgenic mice that overexpress the Dyrk1A exhibited lower levels of phospho-Thr(192)-RCAN1 in 10-month-old-group compared to littermate controls, when analyzed with soluble hippocampus lysates. These results suggest that the phosphorylation of RCAN1 by Dyrk1A stimulates the formation of insoluble aggregates upon aging.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  AD; Aggregation; Aging; Alzheimer's disease; DS; Down syndrome; Dyrk1A; GST; IP; Phosphorylation; RCAN1; TG; WT; dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A; glutathione-S-transferase; immunoprecipitation; pT192-RCAN1; pT212-Tau; phospho-Thr(192)-RCAN1; phospho-Thr(212)-Tau; regulator of calcineurin 1; transgenic; wild-type

Mesh:

Substances:

Year:  2013        PMID: 24021800     DOI: 10.1016/j.neulet.2013.08.066

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.

Authors:  Mir Mohammad Shahroz; Hemant Kumar Sharma; Abdulmalik S A Altamimi; Mubarak A Alamri; Abuzer Ali; Amena Ali; Safar Alqahtani; Ali Altharawi; Alhumaidi B Alabbas; Manal A Alossaimi; Yassine Riadi; Ahmad Firoz; Obaid Afzal
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

2.  Bioinformatics analysis of biomarkers and transcriptional factor motifs in Down syndrome.

Authors:  X D Kong; N Liu; X J Xu
Journal:  Braz J Med Biol Res       Date:  2014-08-08       Impact factor: 2.590

Review 3.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.

Authors:  Arnaud Duchon; Yann Herault
Journal:  Front Behav Neurosci       Date:  2016-06-03       Impact factor: 3.558

4.  Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.

Authors:  T Dang; W Y Duan; B Yu; D L Tong; C Cheng; Y F Zhang; W Wu; K Ye; W X Zhang; M Wu; B B Wu; Y An; Z L Qiu; B L Wu
Journal:  Mol Psychiatry       Date:  2017-02-07       Impact factor: 15.992

5.  Emergence of distinct and heterogeneous strains of amyloid beta with advanced Alzheimer's disease pathology in Down syndrome.

Authors:  Alison M Maxwell; Peng Yuan; Brianna M Rivera; Wilder Schaaf; Mihovil Mladinov; Vee P Prasher; Andrew C Robinson; William F DeGrado; Carlo Condello
Journal:  Acta Neuropathol Commun       Date:  2021-12-27       Impact factor: 7.578

Review 6.  Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome.

Authors:  Helin Atas-Ozcan; Véronique Brault; Arnaud Duchon; Yann Herault
Journal:  Genes (Basel)       Date:  2021-11-20       Impact factor: 4.096

Review 7.  Rodent models in Down syndrome research: impact and future opportunities.

Authors:  Yann Herault; Jean M Delabar; Elizabeth M C Fisher; Victor L J Tybulewicz; Eugene Yu; Veronique Brault
Journal:  Dis Model Mech       Date:  2017-10-01       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.